NTLA
Another data point, another notch in the belt
Intellia’s lonvo-z keeps making the case that one dose might be enough to calm hereditary angioedema, the rare swelling disorder that can turn life into a very unpredictable game of dodgeball. The company says new Phase 3 HAELO findings showed an 87% reduction in mean monthly attacks versus placebo during the weeks-five-through-28 window.
Why Wall Street is paying attention
The big investor takeaway isn’t just that the drug worked — it’s that the results are stacking up. Intellia also said 62% of patients stayed both attack-free and therapy-free over the six-month evaluation period, versus 11% in the placebo arm. That’s the kind of split that makes analysts start sounding less like skeptics and more like people refreshing their BLA checklist.
Safety is still doing its job
The company says tolerability remained favorable, with treatment-emergent adverse events classified as mild or moderate during the primary observation period and no serious adverse events in the lonvo-z group. In biotech land, that’s a pretty big deal: efficacy gets the headlines, but clean safety is what helps the story survive the trip from conference podium to regulator inbox.
The race just got more crowded
There’s also a little competitive theater here. William Blair pointed out that the new data help Intellia look competitive with recently approved HAE therapies, while Ionis’ DAWNZERA is already in the market. So yes, the science is exciting — but this is also a business race, and the finish line is an FDA decision, not a poster presentation.
Big picture: Intellia is trying to turn CRISPR from a buzzword into a business. If lonvo-z keeps this momentum and the rolling BLA lands in the second half of 2026 as expected, NTLA could go from 'promising' to 'please watch this one closely.'